R&D Pipeline

Our Pipeline and Its Potential

Beyond Air Active Pipeline & Market Size

Product Indication Development
Status
Key Dates* US Sales
Potential**
Worldwide Sales
Potential**
LungFitPH
(Pulmonary Hypertension)
In-Hospital use for PPHN and cardiac surgery (country specific) Commercial system in development FDA PMA filing 1Q20

US Launch 2H20
>$300m

Partner
>$600m
LungFitBRO
(Bronchiolitis)
Bronchiolitis Pilot Phase Pivotal Study expected during 2020/2021 Winter

Launch 2022*
>$500m
Beyond Air to commercialize
>$1.2b
LungFitNTM
(Severe Lung
Infections)
NTM
(nontuberculous
mycobacteria)
13 patients treated

2nd pilot study to have higher ppm NO and MAC infection
2020 start for at home pilot study with self-administration

Launch 2024*
>$1b >$2.5b

*All dates are based on projections and appropriate financing, anticipated first launch on global basis pending appropriate regulatory approvals

**All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential

Beyond Air Inactive* Pipeline & Status

All Programs Below are Intended for Patients to Self-Administer at Home

Product Indication Development
Status*
Worldwide Sales
Potential**
LungFit PA pseudomonas aeruginosa Pilot study initiation anticipated in 2021 Multi Billion $
Opportunities
LungFit COPD
(Chronic Obstructive Pulmonary Disease)
Exacerbation caused by any type of infection
(treatment and prevention)
Proof of concept initiation anticipated in 2021
LungFit PAH At-Home Use Proof of concept initiation anticipated in 2022
LungFit CF
(Cystic Fibrosis)
Acute infections and Chronic Therapy Trials anticipated to begin in 2022

*Development of this pipeline is conditional on obtaining additional financing.

**All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential

Important Safety Information

Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.